Last Updated on December 24, 2023 by The Health Master
The US Food and Drug Administration (USFDA) has granted clearance to Analog Pharma and Dipharma’s abbreviated new drug application (ANDA) for 20mg nitisinone capsules.
Nitisinone capsules are hydroxy-phenylpyruvate dioxygenase inhibitors which are used as first-line treatment for a rare condition, hereditary tyrosinemia type 1 (HT-1).
They are available in 2mg, 5mg and 10 mg dosages and are the generic equivalent of Swedish Orphan Biovitrum’s Orfadin.
Nitisinone capsules are indicated for the treatment of adult and paediatric patients with HT-1 in combination with dietary restriction of tyrosine and phenylalanine.
Some of the most common side effects of nitisinone include low platelet count, elevated tyrosine levels, eye pain, white or cloudy cornea from scarring, and pink eye.
Dipharma CEO Marc-Olivier Geinoz said: “For the first time, American HT-1 patients will have access to 20mg capsules, which are stable at room temperature for three years.
“This is the result of the collaboration between Dipharma and our American partner Analog Pharma, which achieved this milestone ahead of time: our next milestone for this year is to extend from two to three years and the stability at room temperature of the lower strength capsules as well.
“Dipharma is a pioneer in developing improved generic pharmaceutical products for rare diseases: our desire to innovate and our engagement do not stop, but every day we continue to seek new and better solutions for patients around the world.”
USFDA gives approval for Diazepam rectal gel
USFDA gives approval for Carboprost Tromethamine Injection
USFDA gives final approval for Ephedrine Sulfate Injection
USFDA gives approval for Brexpiprazole
CDSCO gives approval for Tremelimumab combination in India
Gang selling fake medicines busted in Delhi, UP
USFDA warns about safety risks of tailored weight-loss drugs
USFDA gives approval for Diazepam rectal gel
Chandigarh urges tight monitoring of MRPs in the Pharma Industry
Gas leak at Aurobindo Pharma unit near Hyderabad
Delhi High Court grants Centre 6 weeks to finalize Rules for E-Pharmacies
DPCO 2013: Form 2, 4 & 5 amended to add details including GST rate
Line clearance and maintenance in manufacturing: A comprehensive guide
Difference between Validation and Calibration in the Pharma Industry
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
